Glenmark Pharmaceuticals Ltd Analyst Rating
based on 14 analysts
50.00%
Buy
35.71%
Hold
14.29%
Sell
Based on 14 analysts offering long term price targets for Glenmark Pharmaceuticals Ltd. An average target of ₹1563.43
Source: S&P Global Market Intelligence
Glenmark Pharmaceuticals Ltd Share analysis
Glenmark Pharmaceuticals Ltd price forecast by 14 analysts
Downside of
High
₹1930
Target
₹1563.43
Low
₹570
Glenmark Pharmaceuticals Ltd target price ₹1563.43, a slight downside of -10.07% compared to current price of ₹1716.8. According to 14 analysts rating.
Excluding Excise Duty and Other Income, represents Net Revenue
Glenmark Pharmaceuticals Ltd revenue growth forecast
Expected growth rate Q1, FY2026:30.16%
Forecast
Actual
Including amortisation and stock based compensations
Glenmark Pharmaceuticals Ltd EPS growth forecast
EPS estimate Q1, FY2026:
Forecast
Actual
Source: S&P Global Market Intelligence
Glenmark Pharmaceuticals Ltd Performance
Day's Low
Day's High
₹1,705.05₹1,756.8552 Week's Low
52 Week's High
₹722.1₹1,830.95
| Returns % | |
| 1 Month Return | + 1.52 % |
| 3 Month Return | + 21.6 % |
| 1 Year Return | + 128.77 % |
| Market Stats | |
| Previous Close | ₹1,738.45 |
| Open | ₹1,738.50 |
| Volume | 4.45L |
| Upper Circuit | - |
| Lower Circuit | - |
| Market Cap | ₹49,057.00Cr |
Glenmark Pharmaceuticals Ltd Key Statistics
| P/E Ratio | -37.42 |
| PEG Ratio | 0.67 |
| Market Cap | ₹49,057.00 Cr |
| P/B Ratio | 1.18 |
| EPS | -50.8 |
| Dividend Yield | 0.26 |
| Sector | Pharmaceuticals |
| ROE | 6.98 |
Glenmark Pharmaceuticals Ltd Peer Comparison
Company | Analyst View | Market Cap | 5 Year CAGR | Debt to Asset Ratio | Net Profit | Yearly Revenue |
|---|---|---|---|---|---|---|
| BUY | ₹49,057.00 Cr | 96.25% | 0.52 | -₹1,434 Cr | ₹11,813 Cr | |
| HOLD | ₹31,560.96 Cr | 127.13% | 0.52 | ₹300 Cr | ₹1,051 Cr | |
| BUY | ₹18,791.82 Cr | 30.25% | 0.57 | ₹72 Cr | ₹6,702 Cr | |
| NA | ₹6,996.36 Cr | 12.52% | 0.79 | -₹388 Cr | ₹75 Cr | |
| BUY | ₹14,535.09 Cr | 43.59% | 0.68 | ₹218 Cr | ₹1,296 Cr |
Glenmark Pharmaceuticals Ltd Mutual Fund Holdings
About Glenmark Pharmaceuticals Ltd
Share Price: ₹1716.80 per share as on 21 Oct, 2024 04:01 PM
Market Capitalisation: ₹49,057.00Cr as of today
Revenue: ₹3,223.30Cr as on June 2024 (Q2 24)
Net Profit: ₹340.24Cr as on June 2024 (Q2 24)
Listing date: 07 Feb, 2000
Chairperson Name: Glenn Saldanha
| Organisation | Glenmark Pharmaceuticals Ltd |
| Headquarters | Mumbai |
| Industry | Pharmaceuticals |
| E-voting on shares | Click here to vote |
Key events for Glenmark Pharmaceuticals Ltd
Glenmark Pharmaceuticals Issues Product Recalls in US - 13 Oct, 2024
Glenmark Pharmaceuticals is recalling Ryaltris Nasal Spray and Ciclopirox Gel in the US due to manufacturing issues. The recalls are classified as Class II and Class III by the USFDA, indicating varying levels of health risk.
Glenmark Pharmaceuticals Hits New 52-Week High - 10 Oct, 2024
Glenmark Pharmaceuticals closed at Rs 1,792.50, up 3.34%, breaking its 52-week high of Rs 1,795. The stock has gained 148.23% from its low, indicating strong momentum and potential for continued movement.
Glenmark Life Sciences Rebrands Amid Stock Surge - 09 Oct, 2024
Glenmark Life Sciences announced its rebranding to Alivus Life Sciences after Nirma Limited's acquisition. Meanwhile, Glenmark Pharmaceuticals saw a stock surge, closing at Rs 1,792.50, marking a breakout and strong momentum indicators.
Glenmark Pharmaceuticals Sees 2.21% Surge - 08 Oct, 2024
Glenmark Pharmaceuticals Ltd rose 2.21% to Rs 1712.1, marking a 118.27% increase over the past year. The stock has gained for three consecutive sessions, outperforming both NIFTY and the Nifty Pharma index.
Glenmark Launches National BP Screening Initiative - 01 Oct, 2024
Glenmark Pharmaceuticals, in collaboration with the Association of Physicians of India, launched the Take Charge @18 movement to promote hypertension awareness and early blood pressure monitoring. The initiative aims to educate 10 crore Indians about hypertension, addressing a significant health concern as urban prevalence reaches 40.7%.
Glenmark Investigated for Counterfeit Drug Issues - 27 Sep, 2024
Glenmark Pharmaceuticals is under investigation for counterfeit batches of its anti-hypertension drug Telma H. The company asserts that the products are not manufactured by them.
Glenmark Pharmaceuticals Faces Quality Scrutiny and Counterfeit Claims - 26 Sep, 2024
Glenmark Pharmaceuticals is under scrutiny for quality issues related to Telma H tablets. The company denies involvement with a flagged batch and claims counterfeit products are misattributed to them.
Glenmark Shares Surge After Successful USFDA Inspection - 23 Sep, 2024
Glenmark Pharmaceuticals' stock rose significantly after its Aurangabad facility passed a USFDA inspection with no observations. The company reported strong financial results, including a net profit increase and revenue growth, further enhancing investor sentiment.
Glenmark Pharma's Facility Passes USFDA Inspection - 21 Sep, 2024
Glenmark Pharmaceuticals announced that its Aurangabad facility successfully cleared a USFDA inspection conducted from September 9 to 20, 2024, with zero observations.
Glenmark Pharma's FDA Inspection Success and Profit Surge - 20 Sep, 2024
Glenmark Pharmaceuticals' Aurangabad unit passed an FDA inspection with zero observations. The company reported a significant profit increase, with Q1 net profit rising to ₹340.2 crore.
Insights on Glenmark Pharmaceuticals Ltd
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
POSITIVE IMPACTProfit Spike
Netprofit is up for the last 2 quarters, -1.21K Cr → 340.27 Cr (in ₹), with an average increase of 458.0% per quarter
- POSITIVE IMPACT
FII Holding Up
Foreign Institutions have increased holdings from 20.98% to 23.05% in Sep 2024 quarter
- POSITIVE IMPACT
MF Holding Up
Mutual Funds have increased holdings from 10.92% to 11.41% in Sep 2024 quarter
- POSITIVE IMPACT
Best in 3 Years
In the last 3 years, GLENMARK has outperformed top 5 stocks with highest market-cap in Pharmaceuticals
- POSITIVE IMPACT
Best in 1 Year
In the last 1 year, GLENMARK has outperformed top 5 stocks with highest market-cap in Pharmaceuticals
NO EFFECTPromoter Holding Unchanged
Promoters holdings remained unchanged at 46.65% of holdings in Sep 2024 quarter
NEGATIVE IMPACTRetail Holding Down
Retail Investor have decreased holdings from 18.41% to 17.06% in Sep 2024 quarter
- NEGATIVE IMPACT
Price Dip
In the last 7 days, GLENMARK stock has moved down by -4.4%
- NEGATIVE IMPACT
Revenue Fall
Revenue is down for the last 2 quarters, 3.86K Cr → 3.27K Cr (in ₹), with an average decrease of 15.2% per quarter
Glenmark Pharmaceuticals Ltd Financials
Index Inclusions
Glenmark Pharmaceuticals Ltd Shareholding Pattern
| Investors | Holdings % | FY Quarter | 3M change |
|---|---|---|---|
| Promoter Holdings | 46.65% | 0.00 | |
| Foreign Institutions | 23.05% | 9.84 | |
| Mutual Funds | 11.41% | 4.51 | |
| Retail Investors | 17.06% | ||
| Others | 1.84% |
Glenmark Pharmaceuticals Ltd Key Indicators
Glenmark Pharmaceuticals Ltd Valuation
Glenmark Pharmaceuticals Ltd in the last 5 years
Lowest (-275.05x)
December 28, 2023
Today (-37.42x)
October 18, 2024
Industry (58.10x)
October 18, 2024
Highest (95.94x)
September 14, 2023
Glenmark Pharmaceuticals Ltd Earnings and Dividends
Glenmark Pharmaceuticals Ltd Earnings Results
Glenmark Pharmaceuticals Ltd’s net profit jumped 126.95% since last year same period to ₹340.27Cr in the Q1 2024-2025. On a quarterly growth basis, Glenmark Pharmaceuticals Ltd has generated 127.93% jump in its net profits since last 3-months.
Read More about Earnings ResultsGlenmark Pharmaceuticals Ltd Dividends May,2024
In the quarter ending March 2024, Glenmark Pharmaceuticals Ltd has declared dividend of ₹2.50 - translating a dividend yield of 0.15%.
Read More about Dividends
Glenmark Pharmaceuticals Ltd Technicals Summary
Bearish
Neutral
Bullish
Glenmark Pharmaceuticals Ltd is currently in a Bearish trading position according to technical analysis indicators.
FAQs on Glenmark Pharmaceuticals Ltd
- Get a PAN card.
- Open a Demat account.
- Open a Trading account.
- Link your Demat account to your Trading account.
- Fund your Trading account.
- Place an order to buy Glenmark Pharmaceuticals Ltd shares.
Glenmark Pharmaceuticals Ltd (GLENMARK) share price today is ₹1716.8
Glenmark Pharmaceuticals Ltd is listed on NSE
Glenmark Pharmaceuticals Ltd is listed on BSE
- Today’s highest price of Glenmark Pharmaceuticals Ltd is ₹1756.85.
- Today’s lowest price of Glenmark Pharmaceuticals Ltd is ₹1705.05.
PE Ratio of Glenmark Pharmaceuticals Ltd is -37.42
PE ratio = Glenmark Pharmaceuticals Ltd Market price per share / Glenmark Pharmaceuticals Ltd Earnings per share
Today’s traded volume of Glenmark Pharmaceuticals Ltd(GLENMARK) is 4.45L.
Today’s market capitalisation of Glenmark Pharmaceuticals Ltd(GLENMARK) is ₹49057Cr.
| Glenmark Pharmaceuticals Ltd(GLENMARK | Price |
|---|---|
52 Week High | ₹1830.95 |
52 Week Low | ₹722.1 |
Glenmark Pharmaceuticals Ltd(GLENMARK) share price is ₹1716.8. It is down -6.23% from its 52 Week High price of ₹1830.95
Glenmark Pharmaceuticals Ltd(GLENMARK) share price is ₹1716.8. It is up 137.75% from its 52 Week Low price of ₹722.1
| Glenmark Pharmaceuticals Ltd(GLENMARK | Returns |
|---|---|
1 Day Returns | -21.65% |
1 Month Returns | 1.52% |
3 Month Returns | 21.6% |
1 Year Returns | 128.77% |